A selective NFkB inhibitor, DHMEQ, reduced atherosclerosis in ApoE-deficient mice

Tsuyoshi Chiba, Yoshitaka Kondo, Shohei Shinozaki, Eiji Kaneko, Akihito Ishigami, Naoki Maruyama, Kazuo Umezawa, Kentaro Shimokado*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

41 Citations (Scopus)


Background and Purpose: Atherosclerosis is a chronic inflammatory process, and anti-inflammatory agents potentially inhibit the development of atherosclerosis. We tested whether a novel NFkB inhibitor reduces atherosclerosis. Methods: Dehydroxymethylepoxyquinomicin (10 mg/kg) or vehicle (chloromethyl cellulose) was injected intraperitoneally into apoE-deficient mice three times a week for 16 weeks. The entire aorta was excised and atherosclerotic area was determined at 4 and 16 weeks. Serum levels of cholesterol, triglyceride, TNF-α and adiponectin were also measured. Results: The atherosclerotic area was significantly smaller in mice treated with dehydroxymethyl-epoxyquinomicin both at 4 and 16 weeks. There was no significant difference in body weight or serum levels of cholesterol, triglyceride, and adiponectin. Conclusions: A new NFkB inhibitor, dehydroxymethylepoxyquinomicin, reduced atherosclerosis without affecting plasma lipid levels in apoE-deficient mice.

Original languageEnglish
Pages (from-to)308-313
Number of pages6
JournalJournal of Atherosclerosis and Thrombosis
Issue number6
Publication statusPublished - 2006
Externally publishedYes


  • Hyperlipidemia
  • Inflammation
  • TNF-α

ASJC Scopus subject areas

  • Internal Medicine
  • Cardiology and Cardiovascular Medicine
  • Biochemistry, medical


Dive into the research topics of 'A selective NFkB inhibitor, DHMEQ, reduced atherosclerosis in ApoE-deficient mice'. Together they form a unique fingerprint.

Cite this